NYSE:TMO News 21 January 2026 - 6 February 2026

Thermo Fisher shares fell 2.3% to $578.61 Friday, their fourth straight decline, after management warned of 2026 profit headwinds tied to U.S. research funding cuts. The stock closed about 10% below its 52-week high on heavy volume. Investors are watching Monday’s open for signs of continued selling. Peers Danaher and Waters also slipped.

Thermo Fisher shares fell 2.6% to $592.08 after the company forecast 2026 adjusted profit below Wall Street estimates, citing continued weakness in U.S. academic and government funding. The firm projected 2026 adjusted EPS of $24.22–$24.80 and revenue of $46.3–$47.2 billion. Fourth-quarter revenue rose 7% to $12.21 billion. Investors are watching the timing of the Clario acquisition, expected to close by mid-2026.

Thermo Fisher Scientific shares fell 2.1% to $625.98 on Friday, reversing after a 52-week high the previous day. Trading volume was above average as investors positioned ahead of next week’s earnings and a Federal Reserve meeting. The company’s 1.400% senior notes due 2026 are being delisted from the NYSE. Thermo Fisher reports fourth-quarter results before markets open on Jan. 29.

Thermo Fisher Scientific shares fell 2.1% to $625.98 Friday, ending a three-day rally and retreating from a 52-week high. The drop came ahead of the company’s Jan. 29 earnings release and as peers Waters and Danaher also declined about 2%, signaling profit-taking in the life-sciences tools sector. Investors await updates on Thermo Fisher’s planned Clario acquisition and outlook for 2026.

Thermo Fisher Scientific shares fell nearly 2% by midday Friday, reversing earlier gains after touching a record high near $640. The drop outpaced the broader market, with peers Danaher, Agilent, and Illumina also declining. Investors are awaiting Thermo Fisher’s fourth-quarter results, set for release before the market opens on Jan. 29. The S&P 500 was steady while the health-care sector slipped.

Thermo Fisher Scientific shares fell 1.2% to $631.70 in late morning trading Friday, ending a two-day rally as investors awaited the company’s Jan. 29 earnings report. Peers Danaher and Agilent also declined. Traders are watching for management’s outlook on demand and margins. A recent minor debt security filing drew some attention but did not involve common stock.

Thermo Fisher shares closed up 0.5% at $639.43 Thursday after hitting a new 52-week high, with little change in after-hours trading. The company will report fourth-quarter and full-year results before the market opens Jan. 29. Investors are watching for signals on lab and biopharma spending. Peers Danaher and Agilent slipped, while Waters rose late Thursday.

Thermo Fisher shares rose 1.6% to $628.63 by midday Wednesday, outpacing the broader market ahead of next week’s earnings release. Goldman Sachs raised its price target to $710, maintaining a “buy” rating. The NYSE notified the SEC it will delist Thermo Fisher’s 3.200% senior notes due 2026, affecting only the debt instrument. Investors await the company’s January 29 report and conference call for updates on lab demand and pharma services.